Temporal Programming of Immunomodulatory Agents to Optimize Efficacy and Lower Toxicity of the Anti-Cancer Immune Response

Current project: My thesis project, “Temporal Programming of Immunomodulatory Agents to Optimize Efficacy and Lower Toxicity of the Anti-Cancer Immune Response,” investigates timing of interleukin 2 (IL2), interferon alpha (IFNα), and tumor-specific monoclonal antibodies (mAbs) to optimize therapeutic efficacy and reduce toxic side effects in anticancer immunity. My work then probes the mechanisms of improved toxicity and maintained therapeutic efficacy of temporally designed treatment schedules in the B16F10 tumor model. Lastly, I apply new insight into the most efficacious progression of events in cancer immunotherapy to include other clinical anti-cancer agents in treatment schedules to lower toxicity and improve efficacy.

First project: The mechanism of IgE as a cancer immunotherapeutic was explored in addition to combination treatments with IgG or other immune system modulators.